Skip to content
    Clinical Trials

    Baseline ctDNA Identifies High-Risk Alterations in Ewing Sarcoma

    Mous et alJournal of clinical oncology : official journal of the American Society of Clinical Oncology

    Baseline ctDNA Identifies High-Risk Alterations in Ewing Sarcoma
    In Ewing sarcoma, risk stratification has traditionally relied solely on clinicoradiologic parameters, with limited prospective evidence for molecular risk stratification despite known driver FET::ETS fusions and recurrent secondary alterations such as STAG2, TP53, and CDKN2A. To address this, investigators prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, alongside relapse studies. A total of 991 blood, tumor, and bone marrow samples across 347 patients were profiled using custom targeted sequencing and shallow whole-genome sequencing to perform integrated biologic characterization and clinical correlative analyses.
    The ctDNA profiling recapitulated established genomic landscapes while identifying intrapatient tumor heterogeneity compared with matched tissue biopsies, with blood and bone marrow plasma profiles showing high concordance. Longitudinal sampling identified selection of TP53-altered clones at disease relapse. Clinically, baseline detection of TP53 and/or STAG2 loss-of-function mutations or CDKN2A focal deletions in ctDNA predicted poor outcomes. In a multivariable model controlling for metastatic status, tumor volume, age, and treatment, this defined an independent molecular high-risk subgroup in EE2012 patients with inferior event-free survival (HR, 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001), supporting ctDNA-guided risk stratification.

    Key Takeaways

    • Baseline detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA independently predicted inferior event-free survival (HR, 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) after adjusting for metastatic status, tumor volume, age, and treatment in EE2012 patients.
    • Longitudinal ctDNA monitoring identified the selection of TP53-altered clones at relapse, while blood and bone marrow plasma profiling showed high concordance and revealed intrapatient tumor heterogeneity compared with matched tumor biopsies.
    Read the original sourceJournal of clinical oncology : official journal of the American Society of Clinical Oncology